Acorda Therapeutics, Inc. (ACOR)

$ 3.85
0.05 (+1.32%)
Buy
Symbol ACOR
Price $ 3.85
Beta 0.610
Volume Avg. 0.18M
Market Cap 0.04B
Shares () -
52 Week Range 2.52-9.84
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -48.28% Strong Sell
ROA -21.67% Sell
Operating Margin -
Debt / Equity 183.13% Buy
P/E -
P/B 0.18 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2021 Results - Earnings Call Transcript

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2021 Results - Earnings Call Transcript

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2021 Results - Earnings Call Transcript ...

Seeking Alpha
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock? ...

Zacks Investment Research
Acorda Therapeutics: Buying Before The Coast Is Clear

Acorda Therapeutics: Buying Before The Coast Is Clear

Acorda Therapeutics: Buying Before The Coast Is Clear ...

Seeking Alpha
Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021 ...

Business Wire
Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?

Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?

Is (ACOR) Outperforming Other Medical Stocks This Year? ...

Zacks Investment Research
Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference ...

Business Wire
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2020 Results - Earnings Call Transcript

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2020 Results - Earnings Call Transcript

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2020 Results - Earnings Call Transcript ...

Seeking Alpha
Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates

Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -68.92% and 12.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? ...

Zacks Investment Research
Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021

Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021 ...

Business Wire
Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?

Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?

Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon. ...

Zacks Investment Research

About


Dr. Ron Cohen
Healthcare
Biotechnology
Nasdaq Global Select

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.